Ixekizumab is effective in the long-term management in moderate-to-severe plaque psoriasis: results from an Italian retrospective cohort study (the LOTIXE study)

Ixekizumab is effective in the long-term management in moderate-to-severe plaque psoriasis: results from an Italian retrospective cohort study (the LOTIXE study)

Purpose Ixekizumab is a high-affinity monoclonal antibody that selectively targets interleukin (IL)-17A approved for the treatment of moderate-to-severe plaque psoriasis. The objective of this study was to describe the real-world long-term effectiveness of ixekizumab in patients with plaque psoriasi...

Full description

Bibliographic Details
Main Authors: Andrea Chiricozzi, Matteo Megna, Alessandro Giunta, Carlo Giovanni Carrera, Paolo Dapavo, Anna Balato, Piergiorgio Malagoli, Stella Mazzoccoli, Aurora Parodi, Silvia Sabatino, Carlotta Buzzoni, Chu-Han Huang, Alessandra Narcisi
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Journal of Dermatological Treatment
Subjects:
ixekizumab
plaque psoriasis
psoriasis
autoimmune disease
il-17a inhibitor
real-world evidence
Online Access:http://dx.doi.org/10.1080/09546634.2023.2246606

Internet

http://dx.doi.org/10.1080/09546634.2023.2246606

Similar Items